BACKGROUND: The efficacy of exercise therapy for ankylosing spondylitis (AS) is well-documented, but dearth of information is for non-radiographic axial spondyloarthritis (nr-axSpA). Biomarkers like serum calprotectin, interleukins IL-6, IL-17 and tumour necrosis factor (TNF)-α may reflect the disease activity of axial spondyloarthritis (axSpA). In this study, we investigated clinical and laboratory parameters of both axSpA subgroups in response to intensive physical exercise. METHODS: Altogether, 46 patients with axSpA, characterised according to the Assessment of SpondyloArthritis International Society criteria as having nr-axSpA or AS underwent 6-month exercise programme. Clinical outcomes of disease activity, Bath AS Disease Activity Index (BASDAI), AS Disease Activity Index (ASDAS-CRP), mobility, Bath AS Metrology Index (BASMI) and function, Bath AS Functional Index (BASFI) were evaluated at baseline and at the end of the exercise programme. Serum IL-6 and IL-17, TNF-α and calprotectin were measured via ELISA. The clinical and laboratory data of 29 control axSpA patients were used for the evaluation of the results. RESULTS: In all axSpA patients, the ASDAS-CRP (2.10 ± 0.12 to 1.84 ± 0.11, p <0.01) and BASMI (1.28 ± 0.14 to 0.66 ± 0.84, p <0.0001) improved after 6 months of exercise therapy. There was a significant improvement in the ASDAS-CRP in the nr-axSpA subgroup (2.01 ± 0.19 to 1.73 ± 0.16, p <0.05) and in the BASMI in both, the nr-axSpA and the AS subgroups (1.09 ± 0.12 to 0.47 ± 0.08, p <0.0001 and 1.43 ± 0.24 to 0.82 ± 0.23, p <0.0001, respectively). Both, ASDAS-CRP and BASDAI, were significantly improved in the exercise axSpA group compared to the control axSpA group (mean -0.26 vs. -0.13 and -0.49 vs. 0.12, respectively, all p <0.05). Only calprotectin was significantly reduced after the exercise programme in nr-axSpA and AS patients (from 2379.0 ± 243.20 to 1779.0 ± 138.30 μg/mL and from 2430.0 ± 269.70 to 1816.0 ± 148.20 μg/mL, respectively, all p <0.01). The change in calprotectin was more profound in the axSpA intervention group (mean -604.56) than in the control axSpA (mean -149.28, p <0.05). CONCLUSION: This study demonstrated similar efficacy for an intensive exercise programme in both nr-axSpA and AS patients. A significant decrease in serum calprotectin levels in both subgroups of axSpA patients after the exercise programme reflected an improvement in the disease activity and spinal mobility.

Charles University Faculty of Physical Education and Sport Prague Czech Republic

Department of Rheumatology 1st Faculty of Medicine Charles University and Rheumatology Institute Prague Czech Republic

Zobrazit více v PubMed

Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361–8. doi: 10.1002/art.1780270401. PubMed DOI

Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, Dougados M, Hermann KG, Landewé R, Maksymowych W, van der Heijde D. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68:ii1–ii44. PubMed

Baraliakos X, Braun J. Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences? RMD Open. 2015;1:e000053. doi: 10.1136/rmdopen-2015-000053. PubMed DOI PMC

Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, Dagfinrud H, Dijkmans B, Dougados M, Emery P, Geher P, Hammoudeh M, Inman RD, Jongkees M, Khan MA, Kiltz U, Kvien T, Leirisalo-Repo M, Maksymowych WP, Olivieri I, Pavelka K, Sieper J, Stanislawska-Biernat E, Wendling D, Ozgocmen S, van Drogen C, van Royen B, van der Heijde D. 2010 update of ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70:596–904. PubMed PMC

Sieper J, Poddubnyy D. New evidence on the management of spondyloarthritis. Nat Rev Rheumatol. 2016;12:282–95. doi: 10.1038/nrrheum.2016.42. PubMed DOI

Liang H, Li WR, Zhang H, Tian X, Wei W, Wang CM. Concurrent intervention with exercise and stabilized tumor necrosis factor inhibitor therapy reduced the disease activity in patients with ankylosing spondylitis: a meta-analysis. Medicine (Baltimore) 2015;94:e2254. doi: 10.1097/MD.0000000000002254. PubMed DOI PMC

Millner JR, Barron JS, Beinke KM, Butterworth RH, Chasle BE, Dutton LJ, Lewington MA, Lim EG, Morley TB, O´Reilly JE, Pickering KA, Winzenberg T, Zochling J. Exercise for ankylosing spondylitis: an evidence-based consensus statement. Semin Arthritis Rheum. 2016;45:411–27. doi: 10.1016/j.semarthrit.2015.08.003. PubMed DOI

Nghiem FT, Donohue JP. Rehabilitation in ankylosing spondylitis. Curr Opin Rheumatol. 2008;20:203–7. doi: 10.1097/BOR.0b013e3282f56868. PubMed DOI

Van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, Braun J, Landewé R, Assessment of SpondyloArthritis international Society (ASAS) ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68:1811–8. doi: 10.1136/ard.2008.100826. PubMed DOI

Rudwaleit M, Haibel H, Baraliakos X, Listing J, Märker-Hermann E, Zeidler H, Braun J, Sieper J. The early disease stage in axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum. 2009;60:717–27. doi: 10.1002/art.24483. PubMed DOI

François RJ, Neure L, Sieper J, Braun J. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis. 2006;65:713–20. doi: 10.1136/ard.2005.037465. PubMed DOI PMC

Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, Eggens U, Distler A, Sieper J. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 1995;38:499–505. doi: 10.1002/art.1780380407. PubMed DOI

Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14:585–600. doi: 10.1038/nri3707. PubMed DOI PMC

Gratacós J, Collado A, Filella X, Sanmartí R, Cañete J, Llena J, Molina R, Ballesta A, Muñoz-Gómez J. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol. 1994;33:927–31. doi: 10.1093/rheumatology/33.10.927. PubMed DOI

Mei Y, Pan F, Gao J, Ge R, Duan Z, Zeng Z, Liao F, Xia G, Wang S, Xu S, Xu J, Zhang L, Ye D. Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin Rheumatol. 2011;30:269–73. doi: 10.1007/s10067-010-1647-4. PubMed DOI

De Rycke L, Baeten D, Foell D, Kruithof E, Veys EM, Roth J, De Keyser F. Differential expression and response to anti-TNFalpha treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis. J Pathol. 2005;206:17–27. doi: 10.1002/path.1758. PubMed DOI

Oktayoglu P, Bozkurt M, Mete N, Caglayan M, Em S, Nas K. Elevated serum levels of calprotectin (myeloid-related protein 8/14) in patients with ankylosing spondylitis and its association with disease activity and quality of life. J Investig Med. 2014;62:880–4. doi: 10.1097/JIM.0000000000000095. PubMed DOI

Schreuder KJ, Roelen CA, Koopmans PC, Groothoff JW. Job demands and health complaints in white and blue collar workers. Work. 2008;31:425–32. PubMed

Cumpelik J, Vele F. Yoga-Based Training for Spinal Stability. In: Liebenson C, editor. Rehabilitation of Spine. A Practitioners Manual. Philadelphia: Lippincott Williams and Wilkins; 2006.

Poquet N, Lin CW, Heymans MW, van Tulder MW, Esmail R, Koes BW, Maher CG. Back schools for acute and subacute non-specific low-back pain. Cochrane Database Syst Rev. 2016 PubMed PMC

McKenzie R, May S. The lumbar spine: Mechanical Diagnosis & Therapy. New Zealand: Spinal Publications; 2003.

Brügger A. Gesunde Körperhaltung im Alltag. Stuttgart: G. F. Verlag; 1990.

Altan L, Korkmaz N, Dizdar M, Yurtkuran M. Effect of Pilates training on people with ankylosing spondylitis. Rheumatol Int. 2012;32:2093–9. doi: 10.1007/s00296-011-1932-9. PubMed DOI

Saeterbakken AH, Andersen V, Jansson J, Kvellestad AC, Fimland MS. Effects of BOSU ball(s) during sit-ups with body weight and added resistance on core muscle activation. J Strength Cond Res. 2014;28:3515–22. doi: 10.1519/JSC.0000000000000565. PubMed DOI

Emilio EJ, Hita-Contreras F, Jimenez-Lara PM, Latorre-Román P, Martinez-Amat A. The association of flexibility, balance, and lumbar strength with balance ability: risk of falls in older adults. J Sports Sci Med. 2014;13:349–57. PubMed PMC

Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286–91. PubMed

Calin A, Garrett S, Whitelock H, Kennedy LG, O´Hea J, Mallorie P, Jenkinson T. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing spondylitis Functional Index. J Rheumatol. 1994;21:2281–5. PubMed

Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol. 1994;21:1694–8. PubMed

Karapolat H, Akkoc Y, Sari I, Eyigor S, Akar S, Kirazli Y, Akkoc N. Comparison of group-based exercise versus home-based exercise in patients with ankylosing spondylitis: effects on Bath Ankylosing Spondylitis Indices, quality of life and depression. Clin Rheumatol. 2008;27:695–700. doi: 10.1007/s10067-007-0765-0. PubMed DOI

Kraag G, Stokes B, Groh J, Helewa A, Goldsmith C. The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis-a randomized controlled trial. J Rheumatol. 1990;17:228–33. PubMed

Rosu MO, Topa I, Chirieac R, Ancuta C. Effects of pilates, McKenzie and Heckscher training on disease activity, spinal motility and pulmonary function in patients with ankylosing spondylitis: a randomized controlled trial. Rheumatol Int. 2014;34:367–72. doi: 10.1007/s00296-013-2869-y. PubMed DOI

Ramiro S, Landewé R, van Tubergen A, Boonen A, Stolwijk C, Dougados M, van den Bosch F, van der Heijde D. Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis. RMD Open. 2015;1:e000153. doi: 10.1136/rmdopen-2015-000153. PubMed DOI PMC

Navarro-Compán V, Ramiro S, Landewé R, Dougados M, Miceli-Richard C, Richette P, van der Heijde D. Disease activity is longitudinally related to sacroiliac inflammation on MRI in male patients with axial spondyloarthritis: 2-years of the DESIR cohort. Ann Rheum Dis. 2016;75:874–8. doi: 10.1136/annrheumdis-2015-207786. PubMed DOI

Rosu OM, Ancuta C. McKenzie training in patients with early stages of ankylosing spondylitis: results of a 24-week controlled study. Eur J Phys Rehabil Med. 2015;51:261–8. PubMed

Masiero SBL, Pigatto M, Lo Nigro A, Ramonda R, Punzi L. Rehabilitation treatment in patients with ankylosing spondylitis stabilized with tumour necrosis factor inhibitor therapy: a randomized controlled trial. J Rheumatol. 2011;38:1335–42. doi: 10.3899/jrheum.100987. PubMed DOI

Wallis D, Haroon N, Ayerst R, Carty A, Imman RD. Ankylosing spondylitis and nonradiographic axial spondyloarthritis: part of a common spectrum or distinct diseases? J Rheumatol. 2013;40:2038–41. doi: 10.3899/jrheum.130588. PubMed DOI

Kiltz U, Baraliakos X, Karakostas P, Igelmann M, Kalthoff L, Klink C, Krause D, Schmitz-Bortz E, Flörecke M, Bollow M, Braun J. Do patients with non-radiographic axial spondyloarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res (Hoboken) 2012;64:1415–22. doi: 10.1002/acr.21688. PubMed DOI

Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Märker-Hermann E, Zeidler H, Braun J, Sieper J. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70:1369–74. doi: 10.1136/ard.2010.145995. PubMed DOI

Hansson C, Eriksson C, Alenius GM. S-calprotectin (S100A8/S100A9): a potential marker of inflammation in patients with psoriatic arthritis. J Immunol Res. 2014;2014:696415. doi: 10.1155/2014/696415. PubMed DOI PMC

Andrés Cerezo L, Mann H, Pecha O, Pleštilová L, Pavelka K, Vencovský J, Senolt L. Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. Arthritis Res Ther. 2011;13:R122. doi: 10.1186/ar3426. PubMed DOI PMC

Cypers H, Varkas G, Beeckman S, Debusschere K, Vogl T, Roth J, Drennan MB, Lavic M, Foell D, Cuvelier CA, De Vos M, Delanghe J, van den Bosch F, Elewaut D. Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis. Ann Rheum Dis. 2016;75:1357–62. doi: 10.1136/annrheumdis-2015-208025. PubMed DOI PMC

Gupta L, Bhattacharya S, Agarwal V, Aggarwal A. Elevated levels of serum MRP8/14 in ankylosing spondylitis: associated with peripheral arthritis and active disease. Clin Rheumatol, 2016; in print. doi:10.1007/s10067-016-3448-x. PubMed

Ciccia F, Rizzo A, Triolo G. Subclinical gut inflammation in ankylosing spondylitis. Curr Opin Rheumatol. 2016;28:89–96. doi: 10.1097/BOR.0000000000000239. PubMed DOI

Mortensen OH, Andersen K, Fischer C, Nielsen AR, Nielsen S, Åkerström T, Aastrøm MB, Borup R, Pedersen BK. Calprotectin is released from human skeletal muscle tissue during exercise. J Physiol. 2008;586:3551–62. doi: 10.1113/jphysiol.2008.153551. PubMed DOI PMC

Maharaj A, Slusher AL, Zourdos MC, Whitehurst M, Fico BG, Huang CJ. Association of calprotectin with leukocyte chemotactic and inflammatory mediators following acute aerobic exercise. Appl Physiol Nutr Metab. 2016;41:83–7. doi: 10.1139/apnm-2015-0385. PubMed DOI

Kanda K, Sugama K, Hayashida H, Sakuma J, Kawakami Y, Miura S, Yoshioka H, Mori Y, Suzuki K. Eccentric exercise-induced delayed-onset muscle soreness and changes in markers of muscle damage and inflammation. Exerc Immunol Rev. 2013;19:72–85. PubMed

Acar A, Guzel S, Sarifakioglu B, Guzel EC, Guzelant AY, Karadag C, Kiziler L. Calprotectin levels in patients with rheumatoid arthritis to assess and association with exercise treatment. Clin Rheumatol. 2016;35:2685–92. doi: 10.1007/s10067-016-3240-y. PubMed DOI

Turina MC, Yeremenko N, Paramarta JE, De Rycke L, Baeten D. Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis. Arthritis Res Ther. 2014;16:413. doi: 10.1186/s13075-014-0413-4. PubMed DOI PMC

Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, Landewé R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Wei J, Brachat A, Bek S, Laurent D, Li Y, Wang YA, Bertolino AP, Gsteiger S, Wright AM, Hueber W. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382:1705–13. doi: 10.1016/S0140-6736(13)61134-4. PubMed DOI

Kruithof E, De Rycke L, Vandooren B, De Keyser F, FitzGerald O, McInnes I, Tak PP, Bresnihan B, Veys EM, Baeten D, OMERACT Special Interest Group on Synovial Analysis in Clinical Trials Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis. Arthritis Rheum. 2006;6:1795–804. doi: 10.1002/art.21914. PubMed DOI

Turina MC, Sieper J, Yeremenko N, Conrad K, Haibel H, Rudwaleit M, Baeten D, Poddubnyy D. Calprotectin serum levels is an independent marker for radiographic spinal progression in axial spondyloarthritis. Ann Rheum Dis. 2014;73:1746–8. doi: 10.1136/annrheumdis-2014-205506. PubMed DOI

Klingberg E, Carlsten H, Hilme E, Hedberg M, Forsblad-D´elia H. Calprotectin in ankylosing spondylitis – frequently elevated in feces, but normal in serum. Scan J Gastroenterol. 2012;47:435–44. doi: 10.3109/00365521.2011.648953. PubMed DOI

Smale S, Natt RS, Orchard TR, Russel AS, Bjarnason I. Inflammatory bowel disease and spondyloarthropathy. Arthritis Rheum. 2001;44:2728–36. doi: 10.1002/1529-0131(200112)44:12<2728::AID-ART459>3.0.CO;2-8. PubMed DOI

Meuwis MA, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Piver E, Seidel L, Colombel JF, Louis E, GETAID (Groupe d'Étude Thérapeutique Des Affections Inflammatoires Digestives) Serum calprotectin as a biomarker for Crohn's disease. J Crohns Colitis. 2013;7:e678–83. doi: 10.1016/j.crohns.2013.06.008. PubMed DOI

Boschetti G, Garnero P, Moussata D, Cuerq C, Préaudat C, Duclaux-Loras R, Mialon A, Drai J, Flourié B, Nancey S. Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's disease. Inflamm Bowel Dis. 2015;21:331–6. doi: 10.1097/MIB.0000000000000273. PubMed DOI

Bilski J, Mazur-Bialy A, Brzozowski B, Magierowski M, Zahradnik-Bilska J, Wójcik D, Magierowska K, Kwiecien S, Mach T, Brzozowski T. Can exercise affect the course of inflammatory bowel disease? Experimental and clinical evidence. Pharmacol Rep. 2016;68:827–36. doi: 10.1016/j.pharep.2016.04.009. PubMed DOI

Mathur N, Pedersen BK. Exercise as a mean to control low-grade systemic inflammation. Mediators Inflamm. 2008;2008:109502. doi: 10.1155/2008/109502. PubMed DOI PMC

Wallman JK, Kapetanovic MC, Petersson IF, Geborek P, Kristensen LE. Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients—baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice. Arthritis Res Ther. 2015;17:378. doi: 10.1186/s13075-015-0897-6. PubMed DOI PMC

Schulz M, Dotzlaw H, Neeck G. Ankylosing spondylitis and rheumatoid arthritis: serum levels of TNF-α and its soluble receptors during the course of therapy with etanercept and infliximab. Biomed Res Int. 2014;2014:675108. doi: 10.1155/2014/675108. PubMed DOI PMC

Dorneles GP, Haddad DO, Fagundes VO, Vargas BK, Kloecker A, Romão PR, Peres A. High intensity interval exercise decreases IL-8 and enhances the immunomodulatory cytokine interleukin-10 in lean and overweight-obese individuals. Cytokine. 2016;77:1–9. doi: 10.1016/j.cyto.2015.10.003. PubMed DOI

Sugama K, Suzuki K, Yoshitani K, Shiraishi K, Kometani T. IL-17, neutrophil activation and muscle damage following endurance exercise. Exerc Immunol Rev. 2012;18:116–27. PubMed

Golzari Z, Shabkhiz F, Soudi S, Kordi MR, Hashemi SM. Combined exercise training reduces IFN-γ and IL-17 levels in the plasma and the supernatant of peripheral blood mononuclear cells in women with multiple sclerosis. Int Immunopharmacol. 2010;10:1415–9. doi: 10.1016/j.intimp.2010.08.008. PubMed DOI

Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB, MEASURE 1 Study Group.; MEASURE 2 Study Group Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373:2534–48. doi: 10.1056/NEJMoa1505066. PubMed DOI

Depression and anxiety in individuals with axial spondyloarthritis and nonspecific low back pain who are interested in non-pharmacological therapy options: Cross-sectional study

Changes of patient-reported outcomes and protein fingerprint biomarkers after exercise therapy for axial spondyloarthritis